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Background—Cangrelor is an intravenous ADP receptor antagonist that leads to potent and reversible inhibition of platelet 
aggregation. The relative safety and efficacy of some antiplatelet drugs in women has been disputed.
Methods and Results—The Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition 
(CHAMPION PHOENIX) trial randomized 11 145 patients undergoing elective or urgent percutaneous coronary 
intervention to cangrelor or clopidogrel. The primary efficacy end point was the composite of death, myocardial infarction, 
ischemia-driven revascularization, or stent thrombosis at 48 hours; the key secondary end point was stent thrombosis at 
48 hours. The primary safety end point was GUSTO severe bleeding at 48 hours. Of subjects analyzed, 3051 (28%) were 
female. Cangrelor reduced the odds of the primary end point by 35% in women (adjusted odds ratio [OR], 0.65; 95% 
confidence interval [CI], 0.48–0.89) and by 14% in men (OR, 0.86; 95% CI, 0.70–1.05; P interaction=0.23) compared 
with clopidogrel. Cangrelor reduced the odds of stent thrombosis by 61% in women (OR, 0.39; 95% CI, 0.20–0.77) 
and 16% in men (OR, 0.84; 95% CI, 0.53–1.33; P interaction=0.11). The odds of severe bleeding were similar in both 
women and men treated with cangrelor (0.3% versus 0.2%, P=0.30 [women]; 0.1% versus 0.1%, P=0.41 [men]; P 
interaction=0.88) versus clopidogrel. Cangrelor increased the odds of moderate bleeding in women (0.9% versus 0.3%, 
P=0.02), but not in men (0.2% versus 0.2%, P=0.68; P interaction=0.040). The net clinical benefit (primary efficacy 
and safety end point) favored cangrelor in both women (OR, 0.68; 95% CI, 0.50–0.92) and men (OR, 0.87; 95% CI, 
0.71–1.06; P interaction=0.26).
Conclusions—In CHAMPION PHOENIX, cangrelor reduced the odds of major adverse cardiovascular events and stent 
thrombosis in women and men and appeared to offer greater net clinical benefit than clopidogrel.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01156571.    
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Because women remain underrepresented in clinical tri-als,1,2 there exists uncertainty regarding the relative ben-
efit and risk of established and novel antiplatelet therapies 
in women for the management of cardiovascular disease. In 
particular, concerns have been raised that the relative risk of 
thrombosis and bleeding in response to antiplatelet therapy 
may differ between men and women,3–6 and this may therefore 
influence the net clinical benefit of further intensification of 
antiplatelet therapy for individual patients.
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Cangrelor is a potent intravenous inhibitor of the P2Y12 
receptor that has a rapid onset and a half-life of 3 to 6 min-
utes, with offset of pharmacodynamic effect within 1 hour.7 
Cangrelor’s pharmacological profile is consistent regardless of 
sex, age, or renal or hepatic function.8,9 In patients scheduled to 
undergo elective or urgent percutaneous coronary intervention 
(PCI), cangrelor reduced the incidence of cardiac ischemic 
events and stent thrombosis (ST) as compared to clopidogrel 
without a significant increase in bleeding. Since thrombotic 
and bleeding complications at the time of PCI remain a major 
concern, we examined the relative efficacy and safety of can-
grelor in women versus men in a prespecified analysis of the 
CHAMPION (Cangrelor versus Standard Therapy to Achieve 
Optimal Management of Platelet Inhibition) PHOENIX trial.10
Methods
Patient Population and Study Treatment
The design and results of the CHAMPION PHOENIX trial have 
been previously reported.10,11 In brief, CHAMPION PHOENIX was 
a double-blind, double-dummy trial that enrolled 11 145 patients 
undergoing urgent or elective PCI and randomized them before PCI 
to either cangrelor (iv bolus then infusion) or clopidogrel (300 mg or 
600 mg loading dose) on a background of guideline-recommended 
therapy. At the end of the infusion, patients were administered either 
600 mg of clopidogrel (cangrelor arm) or matching placebo (clopido-
grel arm). Aspirin (75 mg to 325 mg) was to be administered in all 
patients, in addition to a maintenance dose of clopidogrel during the 
first 48 hours. The choice of periprocedural anticoagulant was left to 
the discretion of the treating physician. The use of a glycoprotein IIb/
IIIa inhibitor was allowed only as rescue therapy during PCI.
Patients were considered eligible for enrollment if they were 
≥18 years of age and required PCI for treatment of stable angina or 
an acute coronary syndrome. Relevant exclusion criteria included 
administration of a P2Y12 inhibitor or abciximab in the past 7 days or 
the use of eptifibatide, tirofiban, or fibrinolytic in the 12 hours before 
randomization. Patients were also excluded if they were perceived to 
be at increased risk of bleeding, including ischemic stroke in last year 
or previous hemorrhagic stroke, intracranial aneurysm or arteriove-
nous malformation, recent (<1 month) trauma or major surgery, those 
currently receiving warfarin or with signs of active bleeding.
The study protocol was reviewed and approved by institutional 
review committees and all subjects gave informed consent prior to 
participation.
End Points
The primary efficacy end point was the composite of death from any 
cause, myocardial infarction (MI), ischemia-driven revasculariza-
tion, or ST at 48 hours after randomization. The key secondary end 
point was ST at 48 hours which included definite ST according to 
the Academic Research Consortium definition and intraprocedural 
ST.10,12 As a secondary analysis, efficacy outcomes were collected 
through 30 days. Safety outcomes were only collected through 48 
hours because off-treatment bleeding events that occurred outside 
of the first 2 days would not be anticipated to be study drug-related 
based on the rapid pharmacokinetics of cangrelor.
The key safety end point was severe bleeding not related to 
coronary artery bypass graft according to the GUSTO classifica-
tion system.13 Other bleeding definitions were also applied includ-
ing the Thrombolysis in Myocardial Infarction (TIMI)14 and Acute 
Catheterization and Urgent Intervention Triage strategY (ACUITY)15 
bleeding classifications.
All deaths, cardiac ischemic events, and STs were independently 
adjudicated by a clinical events committee. Bleeding end points were 
not adjudicated, but were captured by the site.
Statistical Analysis
Baseline characteristics were compared using t-tests for continu-
ous variables and χ2 or Fisher exact tests for categorical variables. 
Primary efficacy analyses were conducted in the modified intention-
to-treat population comprising those patients who underwent PCI and 
received study drug. Safety analyses were conducted in the safety 
population that included all patients who underwent randomiza-
tion and received ≥1 dose of the study drug according to the actual 
treatment received. End points are reported as incidence rates at 48 
hours. Difference between treatment groups was tested using the 
Pearson χ2 statistic as well as odds ratios (ORs) and their correspond-
ing 95% confidence intervals (CIs). Analyses were adjusted for any 
imbalances (P<0.10) in baseline characteristics between randomized 
treatment arms when stratified by patient sex. Because the female 
subgroup was relatively underpowered in comparison with the male 
subgroup, potential confounders identified in the male subgroup were 
also included as covariates in the female-only models, including pre-
vious MI, history of heart failure, peripheral arterial disease, previ-
ous coronary artery bypass graft, or abnormal cardiac biomarkers. To 
assess the homogeneity of the crude odds ratios in the sex subgroup 
analyses, a Breslow-Day statistic was used. A multivariable model 
was created to examine independent predictors of the primary effi-
cacy outcome and GUSTO severe or moderate bleeding; a complete 
list of covariates is included in the online-only Data Supplement. 
Nominal P values are reported, and no adjustment was made for the 
comparison of multiple outcomes; all tests were 2-sided with a P 
value <0.05 considered to be significant. Analyses were performed 
using SAS version 9.3 (Cary, NC).
Results
Of 11 145 patients enrolled in the CHAMPION PHOENIX 
trial, 3051 subjects (28%) were female. Women were more 
likely than men to be older and have a history of diabetes mel-
litus, hypertension, hyperlipidemia, previous stroke or tran-
sient ischemic attack, and were more likely to be enrolled in 
the United States in comparison with other regions (Table 1). 
Women were more likely than men to be enrolled with a qual-
ifying event of stable angina or non–ST-segment–elevation 
myocardial infarction whereas men were more frequently 
enrolled with ST-segment–elevation myocardial infarction. 
Women tended to have a lower weight, and were less likely 
to be smokers or have a previous history of MI or coronary 
revascularization. Women had a lower baseline hemoglobin 
and hematocrit than men (Table 1). The choice of clopidogrel 
loading dose and the use of unfractionated heparin and bivali-
rudin were similar for both sexes, but men were more likely to 
be administered aspirin. The median duration of PCI was lon-
ger in men than women, but the choice of access site (femoral 
versus radial) was similar for both sexes (Table 1).
After multivariable adjustment, female sex was indepen-
dently associated with increased odds of the primary effi-
cacy outcome (OR, 1.31; 95% CI, 1.03–1.67) and GUSTO 
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Table 1. Baseline Characteristics in the CHAMPION PHOENIX Trial Stratified by Patient Sex
Women (N=3051)
P Value  
(Cangrelor Versus 
Clopidogrel in Women)
Men (N=7891) P Value  
(Cangrelor Versus 
Clopidogrel in 
Men)
P Value 
(Men 
Versus 
Women)
Cangrelor  
(N=1558)
Clopidogrel 
(N=1493)
Cangrelor  
(N=3914)
Clopidogrel 
(N=3977)
Age (y), median (IQR) 68.0 (60, 75) 68.0 (60, 75) 0.48 63.0 (55, 71) 62.0 (55, 70) 0.40 <0.001
Age ≥65 y, n (%) 974 (62.5) 916 (61.4) 0.51 1671 (42.7) 1699 (42.7) 0.98 <0.001
Age ≥75 y, n (%) 433 (27.8) 413 (27.7) 0.94 589 (15.0) 575 (14.5) 0.46 <0.001
White race, n (%) 1450/1557 (93.1) 1376/1491 (92.3) 0.37 3682/3912 (94.1) 3744/3972 (94.3) 0.79 0.004
Weight (kg), median (IQR) 73.0 (64, 85) 75.0 (65, 85) 0.26 87.3 (78, 98) 87.0 (78, 98) 0.77 <0.001
Dx at presentation, n (%) 0.05
 Stable angina 911 (58.5) 903 (60.5) 0.44 2275 (58.1) 2269 (57.1) 0.33
 NSTEACS 426 (27.3) 379 (25.4) 1038 (26.5) 1049 (26.4)
 STEMI 221 (14.2) 211 (14.1) 601 (15.4) 659 (16.6)
Region, n (%)
 United States 628 (40.3) 606 (40.6) 0.87 1420 (36.3) 1443 (36.3) 0.997 <0.001
 Other countries 930 (59.7) 887 (59.4) 2494 (63.7) 2534 (63.7)
Cardiac biomarker, n (%)
 Abnormal 520/1557 (33.4) 510/1491 (34.2) 0.64 1427/3910 (36.5) 1524/3975 (38.3) 0.09 <0.001
 Normal 1037/1557 (66.6) 981/1491 (65.8) 2483/3910 (63.5) 2451/3975 (61.7)
Diabetes mellitus 509/1557 (32.7) 498/1491 (33.4) 0.68 1010/3907 (25.9) 1038/3972 (26.1) 0.78 <0.001
Current smoker 321/1521 (21.1) 303/1453 (20.9) 0.14 1183/3818 (31.0) 1246/3886 (32.1) 0.30 <0.001
Hypertension 1330/1557 (85.4) 1253/1491 (84.0) 0.29 3044/3902 (78.0) 3079/3963 (77.7) 0.73 <0.001
Hyperlipidemia 1002/1422 (70.5) 970/1359 (71.4) 0.60 2361/3429 (68.9) 2368/3477 (68.1) 0.50 0.02
Previous stroke or TIA 99/1550 (6.4) 86/1490 (5.8) 0.48 172/3905 (4.4) 158/3962 (4.0) 0.36 <0.001
Previous MI 243/1552 (15.7) 268/1487 (18.0) 0.08 849/3889 (21.8) 907/3944 (23.0) 0.22 <0.001
Previous PCI 329/1556 (21.1) 351/1492 (23.5) 0.11 939/3906 (24.0) 982/3969 (24.7) 0.47 0.02
Previous CABG 117/1556 (7.5) 100/1491 (6.7) 0.38 461/3910 (11.8) 400/3973 (10.1) 0.01 <0.001
Previous heart failure 179/1556 (11.5) 160/1490 (10.7) 0.50 373/3904 (9.6) 424/3966 (10.7) 0.09 0.12
Peripheral arterial disease 130/1542 (8.4) 118/1477 (8.0) 0.66 317/3865 (8.2) 267/3942 (6.8) 0.02 0.20
Baseline hemoglobin, median 
(IQR, g/dL)
13.0 (12, 14) 13.1 (12, 14) 0.30 14.2 (13, 15) 14.2 (13, 15) 0.43 <0.001
Baseline hematocrit, median (IQR) 39.0 (36, 41) 39.0 (36, 42) 0.56 42.0 (40, 44) 42.1 (40, 45) 0.46 <0.001
Periprocedural medications, n (%)
Clopidogrel, 300 mg* 399 (25.6) 394 (26.4) 0.62 1006 (25.7) 1007 (25.3) 0.70 0.61
Clopidogrel, 600 mg* 1159 (74.4) 1099 (73.6) 2908 (74.3) 2970 (74.7)
Bivalirudin 342/1558 (22.0) 350/1493 (23.4) 0.33 910/3914 (23.2) 919/3975 (23.1) 0.89 0.58
UFH 1223/1558 (78.5) 1163/1492 (77.9) 0.71 3049/3914 (77.9) 3113/3977 (78.3) 0.69 0.87
LMWH 222/1558 (14.2) 227/1491 (15.2) 0.45 510/3914 (13.0) 526/3977 (13.2) 0.80 0.03
Fondaparinux 44/1558 (2.8) 28/1493 (1.9) 0.08 112/3913 (2.9) 107/3977 (2.7) 0.64 0.23
Aspirin 1447/1556 (93.0) 1396/1491 (93.6) 0.48 3717/3913 (95.0) 3752/3974 (94.4) 0.25 0.005
Duration of PCI (min), median 
N (IQR)
16.0 (9, 26) 15.0 (9, 27) 0.23 18.0 (10, 30) 17.0 (10, 30) 0.19 <0.001
Drug-eluting stent, n (%) 833 (53.5) 804 (53.9) 0.83 2228 (56.9) 2216 (55.7) 0.28 0.012
Bare metal stent, n (%) 692 (44.4) 658 (44.1) 0.85 1616 (41.3) 1686 (42.4) 0.32 0.023
POBA, n (%) 68 (4.4) 79 (5.3) 0.23 224 (5.7) 194 (4.9) 0.09 0.31
Access site
 Femoral 1144 (73.4) 1107 (74.1) 0.33 2909 (74.3) 2904 (73.0) 0.40 0.80
 Radial 413 (26.5) 382 (25.6) 997 (25.5) 1063 (26.7)
 Brachial 1 (0.1) 4 (0.3) 8 (0.2) 10 (0.3)
CABG indicates coronary artery bypass graft surgery; dx, diagnosis; IQR, interquartile range; LMWH, low molecular weight heparin; MI, myocardial infarction; NSTEACS, 
non–ST-segment–elevation acute coronary syndrome; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty; STEMI, ST-segment–elevation 
myocardial infarction; TIA, transient ischemic attack; UFH, unfractionated heparin.
*Intended clopidogrel loading dose at randomization. Per protocol, patients randomized to the cangrelor arm received 600mg clopidogrel after the PCI and infusion.
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moderate or severe (non–coronary artery bypass graft–related) 
bleeding (OR, 2.70; 95% CI, 1.19–6.13).
Efficacy Outcomes With Cangrelor
In women, cangrelor reduced the odds of the primary end 
point by 35% (adjusted OR, 0.65; 95% CI, 0.48–0.89; P=0.01; 
Figure and Table 2) and reduced the odds of ST by 61% 
(adjusted OR, 0.39; 95% CI, 0.20–0.77; P=0.01) as compared 
with clopidogrel. In male patients, cangrelor was associated 
with a 14% reduction in the odds of the primary end point 
(adjusted OR, 0.86; 95% CI, 0.70–1.05; P=0.14; P interac-
tion=0.23; Figure and Table 2) and a 16% reduction in the 
odds of ST (adjusted OR, 0.84; 95% CI, 0.53–1.33; P=0.44; 
P interaction=0.11).
The efficacy of cangrelor in women toward reducing the 
primary end point appeared to be primarily driven by the 
aforementioned reduction in ST, in addition to a 38% reduc-
tion in the odds of MI (adjusted OR, 0.62; 95% CI, 0.44–0.89; 
P=0.01) and a 56% reduction in the odds of ischemia-driven 
revascularization (adjusted OR, 0.44; 95% CI, 0.18–1.08; 
P=0.07; Table 2). In men, cangrelor was associated with a 
12% lower odds of MI (adjusted OR, 0.88; 95% CI, 0.70–1.11; 
P=0.28; P interaction=0.15) and a more neutral effect on the 
odds of ischemia-driven revascularization (adjusted OR, 1.04; 
95% CI, 0.56–1.90; P=0.91; P interaction=0.18; Table 2).
Directionally consistent results were observed when the 
efficacy of cangrelor by patient sex was examined at 30 days 
(Table I in the online-only Data Supplement).
Figure. The Kaplan–Meier incidence of the primary end point of death, MI, ischemia-driving revascularization or stent thrombosis at 
48 hours in women (A) and men (B) in the CHAMPION-PHOENIX trial. The interaction between sex and randomized treatment assignment 
was not significant (P interaction=0.23). CI indicates confidence interval; HR, hazard ratio; and MI, myocardial infarction.
Table 2. Efficacy and Net Clinical Benefit of Cangrelor Versus Clopidogrel Stratified by Sex at 48 Hours
Women Men
P Interaction  
(Rx Arm *Sex)End Point
Cangrelor 
(N=1558) n/N (%)
Clopidogrel 
(N=1493) n/N (%)
Unadjusted OR 
(95% CI) P Value
Adjusted* OR 
(95% CI) P Value
Cangrelor 
(N=3914) n/N (%)
Clopidogrel 
(N=3977) n/N (%)
Unadjusted OR 
(95% CI) P Value
Adjusted* OR  
(95% CI) P Value
Primary end point 74/1557 (4.8) 103/1493 (6.9) 0.67 (0.50–0.92) 
0.01
0.65 (0.48, 0.89) 
0.01
183/3913 (4.7) 219/3976 (5.5) 0.84 (0.69–1.03) 
0.09
0.86 (0.70, 1.05) 
0.14
0.23
Stent thrombosis 12/1557 (0.8) 29/1493 (1.9) 0.39 (0.20–0.77) 
0.005
0.39 (0.20, 0.77) 
0.01
34/3913 (0.9) 45/3976 (1.1) 0.77 (0.49–1.20) 
0.24
0.84 (0.53, 1.33) 
0.44
0.10
MI 56/1557 (3.6) 81/1493 (5.4) 0.65 (0.46–0.92) 
0.01
0.62 (0.44, 0.89) 
0.01
151/3913 (3.9) 174/3976 (4.4) 0.88 (0.70–1.10) 
0.25
0.88 (0.70, 1.11) 
0.28
0.16
Q wave MI 3/1557 (0.2) 7/1493 (0.5) 0.41 (0.11–1.59) 
0.18
0.41 (0.11, 1.60) 
0.20
8/3913 (0.2) 11/3976 (0.3) 0.74 (0.30–1.84) 
0.51
0.73 (0.29, 1.82) 
0.50
0.48
Ischemia-driven 
revascularization
7/1557 (0.4) 15/1493 (1.0) 0.44 (0.18–1.09) 
0.07
0.44 (0.18, 1.08) 
0.07
21/3913 (0.5) 23/3976 (0.6) 0.93 (0.51–1.68) 
0.80
1.04 (0.56, 1.90) 
0.91
0.18
Death from any cause 9/1557 (0.6) 7/1493 (0.5) 1.23 (0.46–3.32) 
0.68
1.25 (0.46, 3.37) 
0.67
9/3913 (0.2) 11/3976 (0.3) 0.83 (0.34–2.01) 
0.68
0.86 (0.36, 2.09) 
0.75
0.56
CV death 9/1557 (0.6) 7/1493 (0.5) 1.23 (0.46–3.32) 
0.68
1.25 (0.46, 3.37) 
0.67
9/3913 (0.2) 11/3976 (0.3) 0.83 (0.34–2.01) 
0.68
0.86 (0.36, 2.09) 
0.75
0.56
Death or stent 
thrombosis
19/1557 (1.2) 35/1493 (2.3) 0.51 (0.29–0.90) 
0.02
0.51 (0.29, 0.90) 
0.02
40/3913 (1.0) 52/3976 (1.3) 0.78 (0.51–1.18) 
0.24
0.84 (0.55, 1.29) 
0.43
0.24
Death, Q wave MI 
or ischemia-driven 
revasc
15/1557 (1.0) 24/1493 (1.6) 0.60 (0.31–1.14) 
0.11
0.59 (0.31, 1.13) 
0.11
34/ 3913 (0.9) 40/ 3976 (1.0) 0.86 (0.54–1.37) 
0.53
0.92 (0.58, 1.47) 
0.74
0.36
Primary +GUSTO 
severe bleeding
78/1557 (5.0) 106/1493 (7.1) 0.69 (0.51–0.93) 
0.02
0.68 (0.50, 0.92) 
0.01
186/3913 (4.8) 221/3976 (5.6) 0.85 (0.69–1.04) 
0.11
0.87 (0.71, 1.06) 
0.17
0.26
Primary+GUSTO 
moderate or severe 
bleeding
92/1557 (5.9) 110/1493 (7.4) 0.78 (0.59–1.05) 
0.11
0.78 (0.58, 1.04) 
0.09
192/3913 (4.9) 230/3976 (5.8) 0.84 (0.69–1.02) 
0.08
0.86 (0.70, 1.05) 
0.14
0.72
CI indicates confidence interval; CV, cardiovascular; GUSTO, Global Utilization Of Streptokinase And Tpa For Occluded Arteries; OR, odds ratio; and MI, myocardial infarction.
*Analyses were adjusted for a history of previous MI, previous heart failure, peripheral arterial disease, previous coronary artery bypass graft, or abnormal cardiac 
biomarkers.
252  Circulation  January 19, 2016
Safety Outcomes With Cangrelor
In both women and men, cangrelor did not increase the odds 
of the primary safety end point, GUSTO severe or life-threat-
ening bleeding, as compared with clopidogrel (0.3% versus 
0.2%, P=0.30; 0.1% versus 0.1%, P=0.41, respectively; P 
interaction=0.88). However, cangrelor increased the odds of 
GUSTO moderate bleeding in women when compared with 
clopidogrel (0.9% versus 0.3%, P=0.02; Table 3). In contrast, 
an excess in GUSTO moderate bleeding was not observed in 
male patients treated with cangrelor as compared to clopi-
dogrel (0.2% versus 0.2%, P=0.68; P interaction=0.04). 
The increase in GUSTO moderate bleeding in women was 
explained by a higher incidence of blood transfusions in can-
grelor-treated women (1.1% versus 0.3%, P=0.01), as com-
pared with those treated with clopidogrel. Cangrelor did not 
increase the odds of blood transfusions in men (0.2% versus 
0.3%, P=0.56; P interaction=0.03). Intracranial hemorrhage 
was infrequent in both men and women and not significantly 
increased with use of cangrelor in either sex (Table 3). There 
were no confirmed fatal bleeding events. Additional bleeding 
end points are shown in Table 3.
Net Clinical Benefit
The net clinical benefit (composite of the primary efficacy and 
safety end points) favored cangrelor as compared with clopi-
dogrel in both women (adjusted OR, 0.68; 95% CI, 0.50–0.92; 
P=0.01) and in men (adjusted OR, 0.87; 95% CI, 0.71–1.06; 
P=0.17; P interaction=0.26). Consistent results were observed 
with cangrelor when moderate bleeding was included in the 
net benefit outcome (primary end point or GUSTO moderate 
or severe bleeding) in both women (adjusted OR, 0.78; 95% 
CI, 0.58–1.04; P=0.09) and men (adjusted OR, 0.86; 95% CI, 
0.70–1.05; P=0.14; P interaction=0.73; Table 2).
Discussion
In the current prespecified subgroup analysis of the 
CHAMPION PHOENIX trial, cangrelor demonstrated a con-
sistent reduction in the odds of major adverse cardiovascu-
lar events (MACE) and ST in both male and female patients. 
In particular, cangrelor reduced the odds of the primary end 
point by 32% and the odds of ST by 61% in female subjects as 
compared with those treated with clopidogrel. By comparison, 
cangrelor was associated with a 15% reduction in the odds of 
MACE and a 16% reduction in the odds of ST in male subjects 
without evidence of heterogeneity by sex. Although some 
previous reports have demonstrated sex-based differences in 
response to some antiplatelet therapies,3–5,16 the observed ben-
efit with cangrelor was consistent in female and male patients.
Although it remains unclear whether true biological differ-
ences exist at the level of the platelet, several previous studies 
have demonstrated that women have higher baseline platelet 
reactivity as compared with men.17–19 Therefore, a strategy of 
platelet inhibition for the prevention of cardiovascular events 
could offer particular appeal in women. Although aspirin has 
a comparable pharmacodynamic response in both women 
and men, women have higher on-treatment platelet reactivity 
Table 3. Safety End Points Stratified by Sex in Safety Population
Women Men
P Interaction 
(Rx Arm *Sex)End Point
Cangrelor 
(N=1583) n/N (%)
Clopidogrel 
(N=1509) n/N (%)
Unadjusted OR 
(95% CI) P Value
Adjusted* OR (95% 
CI) P Value
Cangrelor 
(N=3946) n/N (%)
Clopidogrel 
(N=4018) n/N (%)
Unadjusted OR 
(95% CI) P Value
Adjusted* OR 
(95% CI) P Value
GUSTO severe or 
life-threatening
5/1583 (0.3) 3/1509 (0.2) 1.59 (0.38–6.67) 
0.52
2.37 (0.46,12.33) 
0.30
4/3946 (0.1) 3/4018 (0.1) 1.36 (0.30–6.07) 
0.69
2.04 (0.37,11.19) 
0.41
0.88
GUSTO moderate 15/1583 (0.9) 4/1509 (0.3) 3.60 (1.19–10.87) 
0.02
3.63 (1.20,10.99) 
0.02
7/3946 (0.2) 9/4018 (0.2) 0.79 (0.29–2.13) 
0.64
0.81 (0.30, 2.19) 
0.68
0.040
GUSTO moderate 
or severe
20/1583 (1.3) 7/1509 (0.5) 2.75 (1.16–6.51) 
0.02
3.23 (1.29, 8.08) 
0.01
11/3946 (0.3) 12/4018 (0.3) 0.93 (0.41–2.12) 
0.87
1.04 (0.45, 2.40) 
0.93
0.08
TIMI major 2/1583 (0.1) 1/1509 (0.1) 1.91 (0.17–21.06) 
0.59
2.04 (0.18,22.62) 
0.56
3/3946 (0.1) 4/4018 (0.1) 0.76 (0.17–3.41) 
0.72
1.03 (0.21, 5.13) 
0.97
0.52
TIMI minor 7/ 1583 (0.4) 2/1509 (0.1) 3.35 (0.69–16.14) 
0.11
3.44 (0.71,16.69) 
0.13
2/3946 (0.1) 1/4018 (0.0) 2.04 (0.18–22.47) 
0.55
2.00 (0.18,22.08) 
0.57
0.73
TIMI major or 
minor
9/1583 (0.6) 3/1509 (0.2) 2.87 (0.78–10.62) 
0.10
2.98 (0.80,11.10) 
0.10
5/3946 (0.1) 5/4018 (0.1) 1.02 (0.29–3.52) 
0.98
1.21 (0.32, 4.54) 
0.77
0.25
Any blood 
transfusion
17/1583 (1.1) 5/1509 (0.3) 3.27 (1.20–8.87) 
0.01
4.13 (1.38,12.32) 
0.01
8/3946 (0.2) 11/4018 (0.3) 0.74 (0.30–1.84) 
0.52
0.76 (0.31, 1.90) 
0.56
0.03
ACUITY major 101/1583 (6.4) 59/1509 (3.9) 1.67 (1.21–2.33) 
0.002
1.73 (1.23, 2.41) 
0.001
134/3946 (3.4) 80/4018 (2.0) 1.73 (1.31–2.29) 
<0.001
1.80 (1.36, 2.39) 
<0.001
0.88
ACUITY minor 251/1583 (15.9) 154/1509 (10.2) 1.66 (1.34–2.05) 
<0.001
1.66 (1.34, 2.06) 
<0.001
402/3946 (10.2) 321/4018 (8.0) 1.31 (1.12–1.52) 
<0.001
1.28 (1.10, 1.50) 
0.002
0.08
ACUITY major or 
minor
340/1583 (21.5) 207/1509 (13.7) 1.72 (1.42–2.08) 
<0.001
1.75 (1.44, 2.11) 
<0.0001
516/3946 (13.1) 394/4018 (9.8) 1.38 (1.20–1.59) 
<0.001
1.38 (1.20, 1.58) 
<0.0001
0.07
Fatal bleeding 0/1583 (0.0) 0/1509 (0.0) NA NA 0/ 3946 (0.0) 0/ 4018 (0.0) NA NA NA
Intracranial 
hemorrhage
1/ 1583 (0.1) 0/ 1509 (0.0) NA NA 2/ 3946 (0.1) 1/ 4018 (0.0) NA NA 0.52
ACUITY indicates Acute Catheterization and Urgent Intervention Triage strategY; GUSTO, Global Utilization Of Streptokinase And Tpa For Occluded Arteries; NA, not 
applicable; and TIMI, Thrombolysis in Myocardial Infarction.
*Analyses were adjusted for a history of previous MI, previous heart failure, peripheral arterial disease, previous coronary artery bypass graft, or abnormal cardiac 
biomarkers.
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on aspirin owing to their higher platelet reactivity levels at 
baseline.18 For clopidogrel, some reports have suggested that 
its pharmacodynamic response in women may be attenuated 
thereby leading to a higher proportion of clopidogrel hypore-
sponders.20,21 These observations have contributed to a greater 
need to adequately evaluate novel antiplatelet therapies in 
both women and men. In a meta-analysis of trials for aspirin 
use in the primary prevention of cardiovascular disease, aspi-
rin reduced cardiovascular events in both women and men, but 
the benefit of aspirin in women was primarily toward stroke 
reduction, whereas aspirin reduced the risk of MI in men.5 
In the Antithrombotic Trialists’ Collaboration, the clinical 
benefit of aspirin in women was diminished when compared 
with men when primary and secondary prevention studies 
were combined, but this difference was no longer significant 
once adjusted for multiple comparisons.22 Subsequently, in a 
meta-analysis of randomized trials that studied clopidogrel, 
clopidogrel had comparable efficacy toward MACE reduc-
tion in both women and men, but the benefit of clopidogrel 
in women was driven primarily by a reduction in MI, whereas 
men had a more robust reduction in the risk of MI, stroke, and 
all-cause mortality.23 A meta-analysis of trials of glycoprotein 
IIb/IIIa inhibitors uncovered a significant interaction in effi-
cacy between men and women with a potential signal toward 
harm in female patients. However, when the female popula-
tion was restricted to those with elevated troponin levels, 
there appeared to be a more consistent benefit regardless of 
sex.3 Notably in the current analysis, cangrelor demonstrated 
marked efficacy in women during the periprocedural period 
even though the majority of patients were enrolled with stable 
angina and had normal baseline cardiac biomarkers.
In the current analysis, although severe and life-threatening 
bleeds were similar regardless of treatment arm, we observed 
an increase in the risk of GUSTO moderate bleeding with can-
grelor in women (0.9% versus 0.3%) that was not seen in male 
patients (0.2% versus 0.2%; P interaction=0.04). However, it 
is relevant that the definition of a GUSTO moderate bleeding 
event includes any bleeding that requires transfusion (without 
hemodynamic compromise). Because the decision to transfuse 
is often based on the patient’s hemoglobin concentration, it is 
notable that women had a lower baseline hemoglobin concen-
tration than men at study entry. Therefore, it is plausible that 
this baseline difference between sexes may have contributed 
to a higher frequency of blood transfusions in female patients. 
To that end, the odds of bleeding with cangrelor were more 
comparable in both women and men when alternate bleeding 
definitions were applied. Nonetheless, women overall had a 
higher incidence of bleeding than men regardless of therapy, 
as has been noted in prior PCI analyses,24 and a nonsignifi-
cant trend was observed across alternate bleeding definitions 
toward more bleeding in cangrelor-treated women than those 
treated with clopidogrel. One cannot exclude that higher age, 
a lower body mass index, and other comorbidities in women 
may have explained the observed bleeding signal. Importantly, 
the net clinical benefit that considered both efficacy and bleed-
ing (including GUSTO severe or moderate bleeding events) 
continued to favor cangrelor in both women and men because 
of the marked reduction in MACE in female patients treated 
with cangrelor.
Limitations of the current analysis include the fact that 
tests for heterogeneity are conservative and the trial was not 
powered to examine outcomes within individual subgroups. 
Exploration within patient subgroups may increase the risk 
of a false-positive finding and should therefore be consid-
ered exploratory. As well, randomization was not stratified on 
the basis of patient sex and therefore we cannot exclude that 
unmeasured confounders may have differed across random-
ized treatment arms in either women or men. However, very 
few imbalances were observed between randomized treatment 
arms when stratified by sex because of the large size of the 
trial and all analyses were adjusted for potential confounders. 
Although the GUSTO moderate bleeding definition is based 
on criteria that may have been influenced by the patient’s base-
line hemoglobin, multiple bleeding definitions were included 
in the current analysis.
Because CHAMPION PHOENIX enrolled patients with 
either stable angina (58.1% of patients enrolled) or acute coro-
nary syndrome, the trial did not compare the efficacy or safety 
of cangrelor to prasugrel or ticagrelor, which are now endorsed 
preferentially over clopidogrel in appropriate patients in the 
setting of acute coronary syndrome.25–27 These therapies are 
not currently recommended in the setting of elective PCI and 
were therefore not studied in the current trial. The current sub-
study is underpowered to examine whether efficacy and safety 
were comparable in women or men within the acute coronary 
syndrome or stable angina subgroups.
In summary, the current findings provide important reas-
surance that the efficacy and net clinical benefit of cangrelor at 
the time of PCI is maintained in female patients, a population 
historically understudied in cardiology trials. Efforts should 
continue to identify patient characteristics that may help to 
find those individuals who will derive the greatest net clinical 
benefit from novel antiplatelet therapies.
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CLINICAL PERSPECTIVE
Cangrelor is an intravenous ADP receptor antagonist that leads to potent and reversible inhibition of platelet aggregation. 
The relative safety and efficacy of some antiplatelet drugs in women has been disputed. The CHAMPION PHOENIX trial 
randomized 11 145 patients undergoing elective or urgent percutaneous coronary intervention to cangrelor or clopidogrel. 
Overall the efficacy of cangrelor was similar in men and women with an observed trend toward greater benefit in women. 
The odds of severe bleeding with cangrelor were similar in men and women; however, cangrelor increased the odds of mod-
erate bleeding in women but not in men (P interaction=0.045). In part, this might be explained by lower baseline hemoglobin 
concentration thereby contributing to a higher frequency of blood transfusions in women. Overall, the net clinical benefit 
favored cangrelor over clopidogrel in both women and men undergoing percutaneous coronary intervention.
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